Collectively, these results imply that IL-2 deprivation may dampen the outcomes of NK cell therapy for leukemia patients with a significant effect on NKp30 expression and function, which could be circumvented by the overexpression of a stimulatory NKp30 isoform. This evidence concerns the gene IL2 and leukemia.